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Background: Mutations affecting RNA splicing represent more than 20% of the mutant alleles in Sanfilippo
syndrome type C, a rare lysosomal storage disorder that causes severe neurodegeneration. Many of these mutations
are localized in the conserved donor or acceptor splice sites, while few are found in the nearby nucleotides.
Methods: In this study we tested several therapeutic approaches specifically designed for different splicing
mutations depending on how the mutations affect mRNA processing. For three mutations that affect the donor site
(c.234 + 1G > A, c.633 + 1G > A and c.1542 + 4dupA), different modified U1 snRNAs recognizing the mutated donor
sites, have been developed in an attempt to rescue the normal splicing process. For another mutation that affects
an acceptor splice site (c.372-2A > G) and gives rise to a protein lacking four amino acids, a competitive inhibitor of
the HGSNAT protein, glucosamine, was tested as a pharmacological chaperone to correct the aberrant folding and
to restore the normal trafficking of the protein to the lysosome.
Results: Partial correction of c.234 + 1G > A mutation was achieved with a modified U1 snRNA that completely
matches the splice donor site suggesting that these molecules may have a therapeutic potential for some splicing
mutations. Furthermore, the importance of the splice site sequence context is highlighted as a key factor in the
success of this type of therapy. Additionally, glucosamine treatment resulted in an increase in the enzymatic
activity, indicating a partial recovery of the correct folding.
Conclusions: We have assayed two therapeutic strategies for different splicing mutations with promising results for
the future applications.
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Sanfilippo syndrome or Mucopolysaccharidosis III
(MPS III), is a group of autosomal recessive lysosomal
storage disorders caused by mutations in genes enco-
ding enzymes responsible for heparan sulfate degradation
[1]. There are four types of the disease, depending on the
gene affected. They all present similar clinical symptoms,
including severe central nervous system degeneration ac-
companied by mild somatic manifestations [2]. Sanfilippo* Correspondence: dgrinberg@ub.edu
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unless otherwise stated.syndrome type C (MPS IIIC) is caused by mutations in
the HGSNAT gene. This gene codes for the acetyl-CoA:
α-glucosaminide N-acetyltransferase (EC 2.3.1.78), a pro-
tein localized in the lysosomal membrane which catalyses
the acetylation of the terminal glucosamine residues of
heparan sulphate prior to their hydrolysis by α-N-acetyl
glucosaminidase [3]. The HGSNAT gene, identified by
two independent groups in 2006 [4,5], is located at the
chromosome 8 (8p11.1) and contains 18 exons. The
cDNA encodes a polypeptide of either 635 or 663 amino
acids, since there is a controversy concerning the real ini-
tiation codon [6,7]. To date, 64 mutations have been re-
ported, 16 of which (25%) involve splicing alterations: 13
are described as splicing mutations and three as smallThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Genotype and origin of MPS IIIC affected patients
Patient Origin Allele 1* Allele 2* Reference
SFCP Portugal c.234 + 1G > A c.234 + 1G > A This study
SFC3 Morocco c.234 + 1G > A c.234 + 1G > A [25]
SFC6 Spain c.633 + 1G > A c.1334T > C [25]
SFC7 Spain c.372-2A > G c.372-2A > G [25]
SFC13 France c.1542 + 4dupA c.1150C > T This study
*Mutation nomenclature is based on cDNA sequence (NM_152419.2), with
nucleotide +1 corresponding to the A of the ATG translation initiation codon.
Matos et al. Orphanet Journal of Rare Diseases  (2014) 9:180 Page 2 of 12deletions and duplications that affect the splicing process
(HGMD®Professional Spring 2014.1 Release).
Splicing is an essential step for the expression of most
of human genes, in which the 5’ and 3’ splice sites (ss),
the branch point sequence and the polypyrimidine tract
(both the last two within 50 nucleotides upstream of the
3’ ss) play a fundamental role. These sites present se-
quence variability throughout the human genome. The
splicing process is conducted by the spliceosome, which
is formed of five small nuclear RNAs (snRNAs) and
more than 200 different proteins (reviewed in [8]). The
U1 snRNA, which presents a partially complementary
sequence to the 5’ ss, is essential for the recognition of
the 5’ ss consensus motif (CAG/GTRAGT, exon/intron,
R = purine). The U1 snRNP is composed of a 164-nt
long U1 snRNA and several protein factors. The 5’ re-
gion of the U1 snRNA is involved in the recognition of
the 5’ ss, with the C8 nucleotide being the one that binds
the first nucleotide (G) of the intron (reviewed in [9]).
Application of modified U1 snRNAs to improve recog-
nition of mutated 5’ ss represents a new strategy for re-
covering the normal splicing process. They have been
assayed as a therapeutic approach for different diseases
and splicing mutations affecting different positions of
the 5’ ss with variation in the efficacy of the treatment
[10-19]. Recently, assays correcting an exogenous
injected construct have been performed using modified
U1 snRNAs in mice as a treatment for severe human
factor VII deficiency [20].
In some cases, alternative splicing caused by specific
mutations can give rise to misfolded proteins, which may
be prone to rapid intracellular degradation (reviewed in
[21]). Molecular chaperones are proteins that act on the
correct folding of other polypeptides in cells. Pharmaco-
logical and chemical chaperones are small compounds
that can be used, in a similar way, to avoid the misfolding
of mutant proteins. They are principally potent enzyme
inhibitors which interact specifically with their active sites
to restore the correct folding and to increase stability [22].
In the case of lysosomal storage disorders, once in the
lysosome, the enzyme substrate replaces the chaperone,
thereby completing restoration of enzyme activity [23].
Aminosugars and iminosugars are the most common
pharmacological chaperones used in enzyme enhance-
ment therapy (EET) for lysosomal disorders. EET have
been reported for several of these diseases including Fabry
disease, GM1-gangliosidosis, Morquio B disease, Pompe
disease, Gaucher disease, Krabbe disease, Niemann-Pick
A/B and C diseases; as well as for many other types of
disorders such as retinitis pigmentosa, cystic fibrosis,
Parkinson’s disease, Alzheimer’s disease and cancer (re-
viewed in Ref. [21]). In the case of Sanfilippo syndrome
type C, glucosamine, a competitive HGSNAT inhibitor,
has been shown to increase residual enzyme activity incultured skin fibroblasts from patients affected with a
number of missense mutations [24].
In this work we focus on HGSNAT mutations that
affect the splicing process. Three previously described
splicing mutations [5,25,26] were the object of the study
with different modified U1 snRNAs to improve recogni-
tion of the donor ss and enhance the correct splicing
process. The studies were performed using cells trans-
fected with minigene constructs bearing the specific
mutation as well as cultured patients’ skin fibroblasts.
Mutations include the most frequent change in Moroccan
patients (c.234 + 1G >A), a mutation found in Spanish pa-
tients (c.633 + 1G >A) and a mutation found in a French
patient (c.1542 + 4dupA). Furthermore, EET approach,
was tested for a splicing mutation c.372-2A >G. This mu-
tation is the most prevalent in Spanish and Portuguese pa-
tients [25,27] and affects the acceptor site at the end of
the 4th intron of the HGSNAT gene [27], thereby altering
the splicing process. The use of a downstream alternative
cryptic ss generates an mRNA with an in-frame deletion
that codes for a protein with the loss of four amino acids
(p. [L125_R128del]). Here, we show the effect of this mu-
tation, which reduces enzyme activity, and the recovery of
a part of that activity through treatment with glucosamine
as a chaperone.
Our results show that, depending on the context of
the mutated donor site, modified U1 snRNAs can be a
promising therapeutic tool. The use of glucosamine as a
chaperone improved enzyme activity, suggesting a thera-
peutic effect of this compound for Sanfilippo C patients.
Methods
Mutation analysis of the HGSNAT gene
This study included five MPS IIIC patients: three previ-
ously described, two Spanish and one Moroccan [25]; and
two recently diagnosed, one French and one Portuguese,
carrying mutations already reported by us [25,26] (Table 1).
Studies were approved by the authors’ Institutional Ethics
Committee and conducted under the Declaration of
Helsinki. Patients were encoded to protect their confi-
dentiality. Genetic analysis was performed using control
and patients’ fibroblast cell lines as the source of RNA
and genomic DNA whenever necessary. Total RNA was
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Basel, Switzerland) and converted into cDNA using
High-Capacity cDNA Reverse Transcription Kit (Life
Technologies, Carlsbad, CA) following the manufac-
turers’ instructions. The RT-PCR amplifications were per-
formed using the primers described in Additional file 1:
Table S1 and information regarding specific conditions for
each cDNA amplification and sequence analysis is avail-
able upon request.
Minigene cloning and U1 snRNA expression constructs
For the in vitro splicing approaches, wild type (WT) and
mutant minigenes were constructed for each mutation
under study. A gene fragment including exon 2 and the
flanking intronic regions was amplified from the DNA of
the c.234 + 1G > A patient’s fibroblast cells using the
primers described in Additional file 1: Table S1, and
cloned into the TOPO vector (Life Technologies). The
insert was excised with EcoRI, purified using Wizard®
SV Gel and PCR clean-up system (Promega, Madison, WI),
and subsequently cloned into the pSPL3 vector (Exon
Trapping System, Life Technologies; kindly provided by Dr.
B. Andresen) using the Rapid Ligation Kit (Roche Applied
Science, Mannheim, Germany). Theclone containing the
desired mutant insert in the correct orientation was
identified by restriction enzyme analysis and DNA
sequencing. The exon 6 (c.633 + 1G > A) and exon 15
(c.1542 + 4dupA), together with their intronic flanking
sequences, were also cloned in the pSPL3 vector. These mu-
tated minigenes were ordered from GenScript (Piscataway,
NJ). In all cases, the WT minigenes were obtained by
site-directed mutagenesis using the QuikChange II XL
site-directed Kit (Agilent Technologies, Santa Clara, CA)
following the manufacturer’s instructions and nucleotide
changes were confirmed by sequencing analysis. The
primers used are listed in Additional file 1: Table S1.
To express WT U1 snRNA (U1-WT), we used the vec-
tor pG3U1, which includes the sequence coding for hu-
man U1 ([28]; kindly provided by Dr. F. Pagani). The
different U1 vectors adapted to the donor ss of HGSNAT
exon 2, exon 6 and exon 15 were obtained by site-directed
mutagenesis using the QuikChange II XL site-directed Kit
(Agilent Technologies). For each construct (U1 suppressor
1 to 9) the PCR reaction was performed with the specific
primers shown in Additional file 1: Table S1. The desired
mutations were confirmed by sequence analysis.
Cell culture and U1 transfection experiments
To perform the splicing assays, COS-7 cells and fibro-
blasts were grown in Dulbecco’s modified Eagle’s medium
(Sigma-Aldrich, St. Louis, MO) supplemented with 10%
fetal bovine serum (Life Technologies) and 1% PenStrep
(Life Technologies) at 37°C with 5% CO2. For co-
transfection experiments, COS-7 cells at 90% of confluencewere transfected in 6 or 12-well plates with either 1 or
2 μg of each WT or mutant minigene and 1 to 4 μg of each
different mutation adapted U1 snRNA vector, using Lipo-
fectamine 2000 (Life Technologies) according to the manu-
facturer’s protocol. When required, the amount of DNA
was adjusted with the pSPL3 empty vector. For splicing
analysis of the endogenous HGSNAT transcripts, healthy
control and patients’ fibroblasts at 90% of confluence were
transfected in 6-well plates with 1, 2.5 or 3.5 μg of each
modified U1 snRNA vector using either Lipofectamine
2000 or LTX (Life Technologies) according to the manu-
facturer’s instructions. To estimate transfection efficiency,
healthy control and patients’ cells were transfected with a
control plasmid encoding either GFP or RFP and fluores-
cent cells were monitored by microscopy.
RT-PCR transcript analysis after transfection of modified
U1 snRNAs
Cells were harvested 24 or 48 h after transfection. Total
RNA was extracted using High Pure RNA Isolation Kit
(Roche Applied Science) and converted into cDNA using
High-Capacity cDNA Reverse Transcription Kit (Life
Technologies). The RT-PCR splicing analysis for minigene
transfections was performed using the typical pSPL3
primers SD6 and SA2 (Additional file 1: Table S1). For the
endogenous experiments, RT-PCRs were performed using
the following primers: HGSNAT-Exon 2F/HGSNAT-
Exon 3R for mutation c.234 + 1G > A, HGSNAT-Exon
5F/HGSNAT-Exon 13R for c.633 + 1G >A/c.1334T > C
and HGSNAT-Exon 12F/HGSNAT-Exon 16R for the
c.1542 + 4dupA/c.1150C > T mutation. In the case of
the c.234 + 1G > A mutation, the forward primer was
designed to anneal in the middle of exon 2 to amplify
only the transcripts in which the correct splicing
process was recovered. For the other mutations, the last
nucleotide of one of the primers corresponded to the
point mutation of the other allele (but with the WT nu-
cleotide) to favour that only the cDNA from the splice-
mutation allele was amplified. The RT-PCR products
were sequenced to confirm their identity. All the
primers used are listed in Additional file 1: Table S1
and information regarding the amplification conditions
is available upon request.
Expression of recombinant human mutant and wild type
HGSNAT in COS-7 cells
COS-7 cells cultured in Eagle’s minimal essential medium
supplemented with 10% fetal bovine serum to 70%
confluence were transfected with the pcTAP-HGSNAT
plasmid and mutant pcDNA-HGSNAT-L125_R128del
plasmid as previously described [24]. 48 h after trans-
fection the cells were harvested and analysed for
N-acetyltransferase enzymatic activity or by Western
blot.
Matos et al. Orphanet Journal of Rare Diseases  (2014) 9:180 Page 4 of 12Glucosamine-mediated refolding of mutant HGSNAT
Twenty-four h after transfection with pcTAP-HGSNAT or
mutant pcDNA-HGSNAT-L125_R128del plasmids, COS-7
cells were grown for 72 h in Eagle’s minimal essential
medium supplemented with 10% fetal bovine serum con-
taining 10 mM glucosamine in 6-well plates. Then the cells
were kept for another 24 h in the normal culture medium
without glucosamine. The cells were harvested, lysed by
freeze-thaw in 750 μl of water and assayed for HGSNAT
activity. Three independent experiments (each with 2 cell
plates) were performed on 3 different occasions.
Confluent primary cultures of skin fibroblasts of the
MPS IIIC patient homozygous for the c.372-2A > G mu-
tation and healthy control fibroblasts (n = 5) were grown
in 6-well plates for 72 h in Dulbecco’s minimal essential
medium supplemented with 10% fetal bovine serum
containing 10 mM glucosamine. Then the cells were
kept for another 24 h in the medium without gluco-
samine, harvested, lysed in 500 μl of water and assayed
for HGSNAT activity. Three independent experiments
(each with 2 cell plates) were performed on 3 different
occasions.
Enzyme assay
HGSNAT N-acetyltransferase enzymatic activity was mea-
sured using the fluorogenic substrate 4-methylumbelliferyl
β-D-glucosaminide (4MU-β-GlcN; Moscerdam, Oegstgeest,
Netherlands) as previously described [24]. The protein
concentration was measured according to the method of
Bradford using a commercially available reagent (BioRad,
Hercules, CA).
Statistical analysis
Statistical analysis of the data has been performed by
two-tailed unpaired t-test using the Prism GraphPad
software.
Western blotting
Cell lysates from 3 independent transfections (20 μg of
total protein each) were analysed by Western blot as
previously described [24] using rabbit polyclonal anti-
bodies raised against human HGSNAT Q52-N156 peptide
(Sigma-Aldrich HPA029578, dilution 1:5000, incubation
overnight at 4°C). Detection was performed with an anti-
rabbit IgG antibodies-HRP conjugate (ref. 7074S, Cell
Signalling, Beverly, MA), and the enhanced chemilumi-
nescence reagent (ref. 32106, Thermo Scientific, Waltham,
MA).
Results
Mutation analysis in MPS IIIC patients’ fibroblasts
This study involved four splicing mutations found in five
different patients: SFCP and SFC3 (both homozygous
for c.234 + 1G > A), SFC6 (compound heterozygous forc.633 + 1G > A and the missense mutation c.1334T > C;
p.L445P), SFC13 (compound heterozygous for c.1542 +
4dupA and the nonsense mutation c.1150C > T; p.R384*)
and SFC7 (homozygous for c.372-2A > G) (see Table 1).
For patients SFC3 (previously reported [25]) and SFCP
(novel patient), the RT-PCR analysis of cDNA with pri-
mers in exon 1 and 3 revealed a fragment skipping exon
2 (252 bp) due to the presence of the c.234 + 1G > A mu-
tation in homozygosity (Figure 1A). For patient SFC6
(previously described [25]) the cDNA analysis with
primers in exons 5 and 7 showed two transcripts: one of
a normal length of 172 bp arising from the missense
mutation allele (c.1334T > C; p.L445P); and a second
one resulting from the skipping of exon 6 (102 bp), due
to the splicing alteration c.633 + 1G > A in the other
allele (Figure 1B). For a novel patient, SFC13, bearing
the intron 15 mutation c.1542 + 4dupA in compound
heterozygosity with the c.1150C > T nonsense change in
exon 11, the RT-PCR analysis with primers in exons 11
and 16 revealed two aberrant transcripts. The first one
showed the skipping of exon 15 (395 bp), and in the se-
cond, exon 15 was extended for the first 5 nucleotides of
intron 15 (478 bp) due to the presence of a cryptic ss in
the beginning of this intron (Figure 1C). For the fifth
patient, SFC7 (previously reported [25]), who is homozy-
gous for the c.372-2A >G mutation, the transcript analysis
using primers in exons 3 and 5 revealed the presence of
two transcripts: one of lower size (79 bp) in which exon 4
was skipped; and the other of higher size (189 bp) cor-
responding to a fragment with the deletion of the first 12
nucleotides of exon 4 due to the use of a cryptic 3’ ss loca-
lized downstream of the constitutive one (Figure 1D),
which gives rise to the p.[L125_R128del] mutant protein.
Development of splicing therapy approaches for HGSNAT
gene mutations: minigene assays with modified U1
snRNA vectors
To reproduce the splicing defects in a cellular model that
could be used to test U1 snRNA overexpression as a
therapeutic strategy we constructed several mutant mini-
genes in the pSPL3 vector and expressed them in COS-7
cells. Each of the minigenes bore either one of the three
mutations that affect the donor ss or the WT allele. The
post-transfection cDNA analysis and sequencing revealed
the skipping of exon 2 and exon 6 in the cases of the
c.234 + 1G >A and c.633 + 1G >A mutant minigenes, re-
spectively (Figure 2C,F). For the c.1542 + 4dupA minigene,
the cDNA showed a band that corresponded to the skip-
ping of exon 15 and another band that corresponded to
the inclusion of this exon plus the first five nucleotides of
intron 15 (Figure 2I). Meanwhile, the constructs with the
WT sequences (relative to each mutation) revealed a sin-
gle transcript for each of the three cases with the inclusion
of exon 2, exon 6 or exon 15, respectively. These results
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c.372-2A>G M WT SFC7 C- 
79 bp
189 bp
201 bp
242 bp
190 bp
111/110 bp
147 bp
3 4 5 
C 
c.1542+4dupA 
M WT SFC13 C- 
603 bp
310 bp
281/271 bp
478 bp
395 bp
473 bp
11 14 15 16 
A 
c.234+1G>A M C- WT SFCP SFC3 
500 bp
200 bp
252 bp
1 2 3 
368 bp
B c.633+1G>A 
M WT SFC6 C- 
172 bp
102 bp
242 bp
190 bp
111/110 bp
147 bp
5 6 7 
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172bp 
Figure 1 Analysis of alternative HGSNAT transcripts from the mRNA of five MPS IIIC patients by RT-PCR. RT-PCR amplification of mutations
c.234 + 1G > A (A), c.633 + 1G > A (B), c.1542 + 4dupA (C), and c.372-2A > G (D), and of the WT allele, using the primers indicated in the schemes
by arrows. The different splicing patterns are depicted in the schemes (right), in which the mutations are indicated by black circles. M: marker,
C-: negative control, SFCP, −3, − 6, −13, −7: patients. Boxes in the schemes correspond to exons.
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resemble the patterns observed in control and patients’
cDNAs obtained from fibroblasts. Thus, the minigenes are
reliable tools to test and optimize the overexpression of
modified U1 snRNAs in our attempts to correct the spli-
cing defect.
To evaluate the efficiency of different U1s for correcting
missplicing of the HGSNAT exons 2, 6 and 15, several
constructs, with different degrees of complementarity to
each mutated donor ss, were generated (Figure 2A,D,G).
For each specific case, the WT and mutant splicing re-
porter constructs were co-transfected with the different
U1 snRNAs into COS-7 cells for 24 and 48 h. RT-PCR
analysis was then performed and showed that U1-WT and
the different U1 snRNA modifications do not interfere
with the splicing pattern of any WT minigene (Figure 2B,
E,H).
In the case of the mutant minigenes, different splicing
patterns were observed after overexpression of the diffe-
rent U1 snRNAs. In the case of the mutant c.234 + 1G >A
minigene, the cDNA analysis revealed no change in spli-
cing after co-expression with the U1-WT and U1-sup1
(+ 1T) constructs. With the remaining modified U1s
[U1-sup2 (−1G+ 1T); U1-sup3 (−1G+ 4A); U1-sup4
(−1G+ 1T + 4A)], a band of the size of 376 bp, expected
for the normal splicing, was observed. However, sequenceanalysis showed that the fragment included exon 2 and
the first four base pairs of intron 2 (ATAT), due to the use
of an alternative donor site with the canonical “gt” in
positions +5 and +6. A very faint band corresponding to
exon 2 skipping was still observed when U1-sup2 and U1-
sup3 were overexpressed (Figure 2C).
For the mutant c.633 + 1G >A minigene, the splicing
pattern was not altered after overexpression of U1-WTand
U1-sup5 (+ 1T), while an apparently normal band was de-
tected with the U1 matching all the nucleotides of the mu-
tated donor ss [U1-sup6 (- 1A - 2G - 3A + 1T + 7A + 8T)].
Sequencing of this band demonstrated aberrant splicing
which includes, apart from exon 6, the first four nucleo-
tides (ATAA) of intron 6. Again, this was due to the pre-
sence of an alternative donor site with the canonical “gt” in
positions +5 and +6. A band of low molecular weight,
which corresponded to the skipping of exon 6 was also de-
tected upon U1-sup6 treatment (Figure 2F).
In the c.1542 + 4dupA mutant minigene, the co-
transfection of the totally complementary U1 [U1-sup9
(- 1A - 2A + 5T + 6C + 7A)] induced the appearance of a
single band of the predicted normal size. Sequence ana-
lysis revealed an abnormal fragment including exon 15
and the first five base pairs (GTAAA) of intron 15. As in
the two previous cases, this was due to the presence of a
“gt” in positions +6 and +7 (the duplication of an A in
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Figure 2 Minigene therapeutic approaches with U1 adaptations to correct the pathogenic effect of different donor ss mutations on
the HGSNAT gene. (A), (D) and (G) Schematic illustrations of base pairing between the wild type U1 (U1-WT) and the 5’ ss of wild type and
mutant exons 2, 6 and 15 of the HGSNAT gene. The position of each mutation in the 5’ ss is marked in grey and it is in italics. The different U1
snRNAs used for each mutated 5’ ss of HGSNAT (designated as U1-sup, for suppressor) are also shown. The U1 sequence changes are illustrated in
bold. (B), (C), (E), (F), (H) and (I) RT-PCR analysis of COS-7 cells in which splicing reporter minigenes for each mutation were co-transfected with
the different modified U1 constructs as appropriate. Neither the U1-WT nor the various adapted U1s showed an effect on the splicing of exon 2,
6 or 15 wild type minigenes (B, E and H). In the case of the mutant minigenes, some of the U1 co-transfections [U1-sup2, 3 and 4 (C); U1-sup6
(F); U1-sup7, 8 and 9 (I)] changed the splicing pattern, not to the correct one, but mainly towards an alternative pattern using a “gt” 5’ ss immediately
downstream of the constitutive one. Importantly, the wild type minigene for exon 2 (Mini WT ex2) shows an extra lower band due to the amount of
empty vector added to adjust the total quantity of DNA. Sequencing results for all RT-PCR products are illustrated by schematic drawings. M: molecular
weight marker; NT: non-treated cells; C-: negative control.
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and +6 positions). This band was also observed in the
untreated mutant minigene. The overexpression of U1-
sup7 (−1A-2A) produced an increase in intensity of the
band that corresponded to the use of the alternative site;
while no effect of U1-sup8 (+ 5T + 6C + 7A) or U1-WT
was detected (Figure 2I).
Development of splicing therapy approaches for HGSNAT
gene mutations: treatment of patients’ cells with
modified U1 snRNA vectors
Despite the data of minigene assays showing that the
three ss defects were not corrected by the expression ofthe different modified U1 vectors, we explored the feasi-
bility of this approach to correct the endogenously mis-
spliced HGSNAT transcripts through transfection of the
same U1 variants in patients’ derived cell lines. The spliced
transcripts obtained after transfection of each fibroblast
cell line were analysed by RT-PCR (Figure 3A-F).
Interestingly, for patients SFCP and SFC3, homozygous
for the c.234 + 1G >A mutation, treatment with different
quantities of fully adapted U1 [U1-sup4 (−1G + 1T + 4A)]
resulted in a partial recovery from the splicing defect. Se-
quence analysis revealed two different sequences: one with
the normal splicing; and the other which included the first
four base pairs of intron 2 (Figure 3B and Additional file
Figure 3 Analysis by RT-PCR of the endogenous splicing pattern of control and patients SFCP, SFC3, SFC6 and SFC13 derived fibroblasts
after transfection with different U1 isoforms. (A), (C) and (E) The constitutive splicing of exons 2, 6 and 15 of the HGSNAT gene was not altered in
control fibroblasts after overexpression of U1-WT or any of the modified U1 constructs. (B) In the patients SFCP and SFC3, bearing the homozygous
mutation c.234 + 1G > A, only the fully adapted U1 (2.5 μg of U1-sup4) resulted in partial correction of exon 2 skipping. The same result was obtained
with 1 or 3.5 μg of the U1-sup4 construct (data not shown). (D) and (F) For patients SFC6 and SFC13, bearing genotypes c.633 + 1G >A/c.1334T > C
and c.1542 + 4dupA/c.1150C > T, respectively, the transfection of 2.5 or 3.5 μg of U1-WT or any generated U1 suppressor vector did not produced any
change in the endogenous aberrant splicing pattern. Sequencing results for all RT-PCR products are illustrated by schematic drawings. M: molecular
weight marker; NT: non-treated cells; C-: negative control; RFP: red fluorescent protein.
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COS-7 cells (Figure 2C). To estimate the levels of correct
splicing, the obtained PCR product was cloned in a
pUC19 vector and amounts of around 50% were detected
for the correct sequence (10 out of 22 clones with the
correct spliced fragment). Due to this partial correction
obtained, an experiment to measure the enzymatic activity
in patient’s cells after U1-sup4 transfection was carried
out. However, no improvement in enzyme activity was ob-
served. The values obtained for both patients, without
treatment and using 2.5 μg U1sup4, were negligible and
far below the normal range of controls (1.95-13.4 nmol/
17 h/mg). The expression of the remaining U1 modifica-
tions had no detectable effect on exon 2 splicing.
In the case of the patients SFC6 (c.633 + 1G >A/
c.1334T > C) and SFC13 (c.1542 + 4dupA/c.1150C > T),
the RT-PCR analysis showed no effect of any modified U1
snRNA on the endogenous splicing process (Figure 3D,F).Similarly, WT HGSNAT gene splicing was not affected by
any of the U1 isoforms (Figure 3A,C,E).
To rule out the possibility of the negative results being
due to poor fibroblast transfection efficiency, fluo-
rescence expression GFP/RFP vectors were used; effi-
cient acquisition of the vectors was observed (data not
shown). The uptake of the U1 snRNA was confirmed by
PCR (Additional file 3: Figure S2). Moreover, the electro-
poration technique was also tried but no improvement
in transfection efficiency was achieved (data not shown).
Analysis of the protein encoded by the mutant HGSNAT
cDNA with 12 nucleotides deleted
In order to test whether mutant cDNA with a 12-
nucleotide in-frame deletion (encoding p.[L125_R128del])
produces a stable protein and, if so, whether it is enzyma-
tically active, we transfected cultured COS-7 cells with a
corresponding pcDNA-HGSNAT-L125_R128del plasmid
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ogenate. Cells transfected with an empty plasmid or those
transfected with the pcTAP-HGSNAT plasmid described
previously [6] encoding WT human HGSNAT were used
as positive and negative controls, respectively. Our data
(Figure 4A) showed a small but significant increase of
N-acetyltransferase activity in the cells transfected with
the mutant HGSNAT compared to that in the cells trans-
fected with the empty plasmid. The activity in the cells
transfected with WT pcTAP-HGSNAT increased about
10-fold (Figure 4A).
We further analysed cell homogenates by Western blot
and detected a cross-reacting band in the cells trans-
fected with both WT and mutant plasmids (Figure 4B).
The amount of 160 kDa dimer of the HGSNAT pre-
cursor was comparable in both homogenates, but the
amount of 44 kDa and 25 kDa enzymatically cleaved
mature HGSNAT chains was reduced in the cells trans-
fected with the pcDNA-HGSNAT-L125_R128del plas-
mid. Since the enzymatic cleavage of the HGSNAT
precursor into the 2-chain form occurs in the lysosome
[6], this result is consistent with misfolding of the majo-
rity of the HGSNAT-L125_R128del mutant and its re-
tention in the endoplasmic reticulum (ER), as previously
demonstrated for most HGSNAT mutants with amino
acid substitutions [24].Figure 4 Enzymatic activity of mutant HGSNAT-L125_R128del protein
glucosamine. (A) N-acetyltransferase activity of COS-7 cells transfected wit
compared to that of cells transfected with the empty pcDNA plasmid (moc
transfections (each in duplicate) were performed on separate occasions.**
p < 0.001, respectively) according to unpaired t-test. (B) COS-7 cells transfec
dimmers and 78 kDa monomers of HGSNAT precursor protein but show d
chains produced by intra-lysosomal enzymatic cleavage. Panel shows repre
activity of COS-7 cells transfected with the pcDNA-HGSNAT-L125_R128del
for the c.372-2A > G mutation is significantly increased after treating the ce
means (±S.D.) of individual measurements. Three independent experiments
**: statistically different from untreated cells (p < 0.05 and p < 0.01, respectiPartial recovery of the enzyme activity of
p.[L125_R128del] by glucosamine as a pharmacological
chaperone
Our previous data demonstrated that the treatment of
cultured cells of MPS IIIC patients bearing missense
mutations with the competitive HGSNAT inhibitor
(Ki = 0.28 mM) glucosamine, significantly increased the
level of the residual N-acetyltransferase activity [24]. In
order to determine whether glucosamine can also re-
store the folding and activity of the p.[L125_R128del]
mutant protein, we treated COS-7 cells transfected with
the pcDNA-HGSNAT-L125_R128del plasmid and cul-
tured primary fibroblasts of the patient homozygous for
the c.372-2A > G mutation with 10 mM glucosamine.
Our data (Figure 4C) show that glucosamine significantly
increases residual N-acetyltransferase activity in both
COS-7 cells transfected with the pcDNA-HGSNAT-
L125_R128del plasmid and in the patient’s fibroblasts.
This suggests that the active conformation of the mutant
HGSNAT can be stabilized by glucosamine, resulting in
part of the mutant enzyme pool being properly processed
and targeted at the lysosomes.
Discussion
In this study we describe two therapeutic approaches
specific for several splicing mutations in the HGSNATcan be partially restored by the pharmacological chaperone,
h the pcDNA-HGSNAT-L125_R128del plasmid is significantly increased
k). The data show means (±S.D.) of individual measurements. Three
and ***: statistically different from mock-transfected cells (p < 0.01 and
ted with the pcDNA-HGSNAT-L125_R128del plasmid produce 160 kDa
rastically reduced amounts of 44 kDa and 25 kDa mature HGSNAT
sentative data of 3 independent transfections. (C) N-acetyltransferase
plasmid and of cultured primary fibroblasts of the patient homozygous
lls in culture with 10 mM glucosamine for 72 h (+GA). The data show
measurements were performed each of them with 2 cell plates. * and
vely) by unpaired t-test.
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Sanfilippo C patients, each carrying at least one splicing
mutation. To our knowledge, this is the first attempt to
treat Sanfilippo syndrome type C splicing mutations with
modified U1 snRNAs. The chaperone treatment, the
second therapeutic strategy examined in the present
work, was previously tested in vitro for several missense
Sanfilippo C syndrome mutations with promising results
[24] and it is applied here for the treatment of a mutant
protein lacking four amino acids.
For patients carrying mutations in the donor ss (SFCP,
SFC3, SFC6 and SFC13), modified U1 snRNAs have
been tested as a therapeutic tool to recover the normal
splicing process. This approach has previously been tes-
ted for different mutations in several disorders showing
different efficiencies at rescuing the normal transcripts
[10-19]. A total of 9 different U1s have been developed,
as well as the U1-WT. None of them affected the nor-
mal splicing process in WT minigenes or healthy control
fibroblasts when overexpressed.
Few assays to correct a +1 5’ ss mutation have been re-
ported. In some of those, the efficiency of modified U1
snRNAs for splicing mutations in canonical positions +1
and +2 has been shown to be inexistent [10,13]. However,
Hartmann et al. [19] showed a partial correction of a +1
mutation in a case in which some degree of normal spli-
cing was conserved in the mutant allele and the alternative
donor site with a “gt” dinucleotide in positions +5 and +6
presented a low score according to different predictors. In
this report, we present three cases with splicing mutations
at position +1, two homozygous patients with the c.234 +
1G >A mutation (SFCP and SFC3) and one heterozygous
patient with the c.633 + 1G >A mutation (SFC6). When
we analysed the treatment efficiency of different modified
U1 snRNAs in minigene constructions carrying these
mutations, we were not able to detect restoration of the
normal splicing process. Instead, we detected alternative
splicing patterns due to the use of highly conserved “gt”
nucleotides at positions +5 and +6 as a donor site, giving
rise to a transcript that includes 4 intronic nucleotides.
This result was obtained using three of the four modified
U1 snRNAs for the c.234 + 1G >A mutation and the total
complementary U1 snRNA for the c.633 + 1G >A muta-
tion. Due to the presence of these “gt” dinucleotides at
position +5 and +6 in many introns, it is important to se-
quence putative rescued transcripts to check whether this
alternative site was used.
Despite these results, and taking into account that mini-
genes only included partial intronic sequences which could
lack some splicing regulatory sites and that they were
assayed in non-human cells, modified U1 snRNAs were
tested on patients’ fibroblasts. Partial rescue (almost 50%)
of the normal splicing for the c.234 + 1G >A mutation was
observed in patients SFCP and SFC3 overexpressing theU1-sup4. In the case of the c.633 + 1G >A mutation (pa-
tient SFC6), no rescue was observed after the modified U1
snRNAs overexpression. Analysis of the ss sequences using
the Human Splicing Finder predictor [29], indicated that
the alternative site of patient SFC6 had a high score
(68.17/100), while that of patients SFCP and SFC3 had a
null score. This could explain the difference in the rescue
results between these two “+1” mutations: the mutant al-
lele of patient SFC6 would efficiently use the alternative
site and, thus, would not be rescued.
The molecular reason why the modified U1 promotes,
in general, a new splicing process using the +5 + 6 “gt”
donor site when its sequence perfectly matches the mu-
tated +1 + 2 site remains unclear. One explanation could
be the involvement of U6 snRNA complementarity, in
addition to that of U1, in the choice of alternative ss in
proximity to the normal one, which has been previously
described [30,31].
The rescue of the splicing mutation shown here is one
of the few positive results for a “+1” mutation using a
modified U1 snRNA and the first one performed on an
allele that did not produce any of the correctly spliced
mRNAs when untreated. It is important to note that a
few natural U2-type 5’ ss that present “au” instead of the
normal “gu” at the first two nucleotides of the intron
have been described [32,33]. These introns present “ac”
instead of “ag” at the last two nucleotides. Thus, one
could think that mutated “au” sites could promote an al-
ternative splicing using an “ac” acceptor site. However,
for this +1 mutation the “au-ac” alternative splicing type
was not observed. On the contrary, we found that the
“au” 5’ ss correctly paired with the normal “ag” and not
with a possible cryptic “ac” 3’ ss, restoring the normal
splicing of intron 2.
Further studies are needed to improve the efficacy and
to test the toxicity and side effects of U1 overexpression
in order to confirm the feasibility of the use of this
modified U1 snRNAs in therapy. Overexpression of U1
snRNA vectors introduced with adeno-associated virus
into mice liver has been shown to be toxic at high viral
doses but safe at low doses, suggesting the viability of
this treatment when low amounts of U1 snRNA viral
particles are injected [20].
In the case of the c.1542 + 4dupA mutation (patient
SFC13), it is important to note that the canonical “gt” site
is not affected by the mutation. However, in this case there
is also another “gt” dinucleotide in positions +6 and +7
(one nucleotide downstream due to the duplication). The
minigene analysis showed that the splicing that uses the
alternative donor site occurs, even without treatment,
together with that causing exon 15 skipping. This alterna-
tive splicing is slightly enhanced with U1-sup7 and greatly
enhanced with U1-sup9. Many different ss predictors were
used in order to estimate the score for each donor site in
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sence of mutation, the scores of both sites are similar; but
when the mutation is present, the normal site presents a
lower score while the alternative site increases its score.
This is consistent with the fact that in the presence of the
mutation the alternative “gt” site is the only one used (see
Figure 2I). As it was previously discussed, it remains un-
clear why the modified U1 snRNAs, designed to perfectly
match the mutated site, enhance the splicing using the al-
ternative site. When the modified U1 snRNAs were tested
on patient’s fibroblasts, no rescue was detected: either for
the normal mRNA or for the one including the five in-
tronic nucleotides. The latter was detected without any
treatment, indicating that it takes place in normal condi-
tions in the patient’s cells. In any case, the alternative tran-
script would not restore the enzyme activity since it does
not keep the frame, so it could not have any therapeutic
use. Many different mutations in the +3 to +6 positions
have been partially or totally rescued using U1 snRNAs
[10-13,15,17,18], while one +5 mutation was not corrected
[15]. Our current results point to the importance of the
presence of an additional “gt” dinucleotide in the region
which, depending on the sequence context, may be used
as an alternative donor site. In previous reports where
mutations have been partially or totally corrected and the
“gt” dinucleotide was present at positions +5 and +6
[15,19], the alternative site presented a low score in ac-
cordance with different predictors, in contrast to the cases
described here.
Finally, we attempted to rescue the c.372-2G > A mu-
tation (present in SFC7), using molecular chaperone.
This mutation gives rise to two different splicing pro-
cesses in fibroblasts: one causing exon 4 skipping; the
other using an alternative acceptor site, 12 nucleotides
downstream of the normal site and producing a tran-
script with an in-frame deletion. We showed that this
alternative splicing produces a protein lacking 4 amino
acids p. [L125_R128del] that has some residual activity
but the majority of the protein does not reach the lyso-
some, remaining in the ER due to its misfolding.
In order to restore the correct protein folding, cells
transfected with the plasmid carrying the mutant protein
and the patient’s fibroblasts were treated with glucosamine
chaperone, which resulted in a significant increase in the
residual HGSNAT activity. This indicates the feasibility of
this therapeutic approach for patients carrying this splicing
mutation. Different chaperones assays for lysosomal disor-
ders have been performed before and some have been
tested in humans, showing their safety and potential as a
therapeutic tool (reviewed in Ref. [21]).
Conclusions
In conclusion, the results of two therapeutic approaches
for different splicing mutations varied depending on thenature of the mutation. For the treatment of donor ss
mutations, U1 snRNAs could represent a feasible option.
This would depend on the presence of alternative donor
sites close to the normal site that could interfere with
the correction process and, thus, with the success of the
therapy. This is important since many introns present a
“gt” in positions +5 and +6. In the present study, we
have shown that it is possible to partially recover the
normal splicing process for +1 mutations, which was re-
ported only once before. Additionally, a chaperone treat-
ment using glucosamine for a mutant protein with a loss
of 4 amino acids, caused by an acceptor ss mutation, has
been shown to result in a significant increase in the en-
zyme activity. These promising results encourage further
research into the therapeutic use of U1 snRNAs and
chaperones to treat Sanfilippo syndrome type C patients.Availability of supporting data
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